{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:52:16Z","timestamp":1775688736425,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,14]]},"DOI":"10.7759\/cureus.9192","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T01:13:17Z","timestamp":1594775597000},"source":"Crossref","is-referenced-by-count":7,"title":["Pembrolizumab-Induced Ocular Myasthenic Crisis"],"prefix":"10.7759","author":[{"given":"Christian J","family":"Lorenzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Campdesuner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Lattanzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Cancer treatment and chemotherapy","author":"Cordes LM","year":"2017","unstructured":"Cordes LM, Shord SS. Cancer treatment and chemotherapy. Pharmacotherapy: A Pathophysiologic Approach, 10e. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (ed): McGraw-Hill, New York; 2017. 1:2029-2077."},{"key":"ref2","article-title":"Myasthenia gravis and other diseases of the neuromuscular junction","author":"Amato AA","year":"2018","unstructured":"Amato AA. Myasthenia gravis and other diseases of the neuromuscular junction. Harrison's Principles of Internal Medicine, 20e. Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (ed): McGraw-Hill, New York; 2018. 1:3232-3238."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious D","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017, 82:128-136. 10.1016\/j.ejca.2017.05.041","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1956-18","article-title":"Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy","volume":"58","author":"Onda A","year":"2019","unstructured":"Onda A, Miyagawa S, Takahashi N, et al.. Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy. Intern Med. 2019, 58:1635-1638. 10.2169\/internalmedicine.1956-18","journal-title":"Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13499","article-title":"Pembrolizumab\u2010associated ocular myasthenia gravis","volume":"47","author":"Liu Q","year":"2019","unstructured":"Liu Q, Ayyappan S, Broad A, Narita A. Pembrolizumab\u2010associated ocular myasthenia gravis. Clin Exp Ophthalmol. 2019, 47:796-798. 10.1111\/ceo.13499","journal-title":"Clin Exp Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki S","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, et al.. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017, 89:1127-1134. 10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000310","article-title":"Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients","volume":"27","author":"Nguyen BH","year":"2017","unstructured":"Nguyen BH, Kuo J, Budiman A, Christie H, Ali S. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res. 2017, 27:152-154. 10.1097\/CMR.0000000000000310","journal-title":"Melanoma Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"137","author":"Fellner A","year":"2018","unstructured":"Fellner A, Makranz C, Lotem M, et al.. Neurologic complications of immune checkpoint inhibitors. J Neurooncol. 2018, 137:601-609. 10.1007\/s11060-018-2752-5","journal-title":"J Neurooncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25163","article-title":"Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer","volume":"54","author":"Polat P","year":"2016","unstructured":"Polat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve. 2016, 54:507. 10.1002\/mus.25163","journal-title":"Muscle Nerve"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.145987","article-title":"Ocular myasthenia gravis: a review","volume":"62","author":"Nair AG","year":"2014","unstructured":"Nair AG, Patil-Chhablani P, Venkatramani DV, Ghandi RA. Ocular myasthenia gravis: a review. Indian J Ophthalmol. 2014, 62:985-991. 10.4103\/0301-4738.145987","journal-title":"Indian J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/jop.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary","volume":"14","author":"Brahmer J","year":"2018","unstructured":"Brahmer J, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract. 2018, 14:247-249. 10.1200\/jop.18.00005","journal-title":"J Oncol Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/31371-pembrolizumab-induced-ocular-myasthenic-crisis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:18:58Z","timestamp":1707506338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/31371-pembrolizumab-induced-ocular-myasthenic-crisis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.9192","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,14]]}}}